lefitolimod

Lefitolimod is a synthetic, covalently closed DNA molecule that acts as an agonist of toll-like receptor 9 (TLR-9). It is taken up by subsets of dendritic cells and B cells mimicking bacterial or viral infection. Consequent production of pro-inflammatory cytokines enhances antigen presentation by these cells, stimulates innate and adaptive immune responses and anti-tumor activity. Oncologie’s focus is on the exploration of lefitolimod’s ability to enhance activity of checkpoint inhibitors as therapy for various cancers.

lefitolimod

Lefitolimod is a small, covalently closed dna molecule that acts as an agonist of toll-like receptor 9 (tlr-9) agonist. It is taken up by subsets of dendritic cells and b cells mimicking bacterial or viral infection. Consequent production of pro-inflammatory cytokines enhances antigen presentation by these cells, stimulates innate and adaptive immune responses and anti-tumor activity. TLR9 agonists enhance checkpoint inhibitor therapy in a multiple cancers.

on-going trials

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist)

in Patients With Advanced Solid Malignancies

Link

Evaluation of MGN1703 Maintenance Treatment in Patients

With mCRC With Tumor Reduction

During Induction Treatment (IMPALA)

Link

on-going trials

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment (IMPALA)

 

This website uses cookies. By continuing to use this website you are giving consent to cookies being used.